ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: hospital

Upadacitinib Promising for RA in Phase 3 Study

Michele B. Kaufman, PharmD, BCGP  |  December 5, 2017

In a recent study, upadacitinib proved safe and effective to treat rheumatoid arthritis in patients with inadequate responses to conventional synthetic DMARDs…

Filed under:Biologics/DMARDsDrug Updates Tagged with:Rheumatoid Arthritis (RA)upadacitinib

CVS Health to Acquire Aetna for $69 billion

Carl O'Donnell & Caroline Humer  |  December 4, 2017

(Reuters)—U.S. drugstore chain operator CVS Health Corp said on Sunday it had agreed to acquire U.S. health insurer Aetna Inc. for $69 billion, seeking to tackle soaring healthcare spending through lower-cost medical services in pharmacies. This year’s largest corporate acquisition will combine one of the nation’s largest pharmacy benefits managers (PBMs) and pharmacy operators with…

Filed under:Legal Updates Tagged with:Aetna Inc.CVS Health CorpCVS pharmaciesLegalmerger

Multimodal Imaging May Uncover Neural Mechanisms in Pediatric Neuropsychiatric Lupus

Carina Stanton  |  December 1, 2017

In clinical practice, many unknowns exist about how SLE affects the brain—particularly in children. To help these young children battling pediatric SLE, Andrea Knight, MD, MSCE, is examining how advanced neuroimaging techniques may uncover potential inflammatory and non-inflammatory mechanisms of neuropsychiatric dysfunction in lupus…

Filed under:ConditionsSystemic Lupus Erythematosus

European Commission Approves Subcutaneous Belimumab for SLE; FDA Safety Alert for Febuxostat

Michele B. Kaufman, PharmD, BCGP  |  November 29, 2017

Subcutaneous belimumab has been approved in the EU to help treat patients with active autoantibody-positive SLE…

Filed under:ConditionsDrug UpdatesGout and Crystalline Arthritis Tagged with:belimumabcardiovascularEuropean UnionFebuxostatGoutInternationalsystemic lupus erythematosus (SLE)

Bisphosphonate Drug Holiday & Hip Fracture Risk

Michele B. Kaufman, PharmD, BCGP  |  November 21, 2017

New research found women on bisphosphonate therapy who take a drug holiday experience a higher rate of hip fracture…

Filed under:ConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:bisphosphonatesdrug holidayFractureshiphip fracturehip fracture riskOsteoporosisosteoporosis treatments

Year in Review: Expert Covers 2017’s Key Clinical Findings

Thomas R. Collins  |  November 20, 2017

In a Year in Review session at the 2017 ACR/ARHP Annual Meeting, Daniel Solomon, MD, MPH, highlighted the latest and most intriguing aspects of clinical research on rheumatic diseases from 2017. His discussion touched on medical therapy, genetics, the effects of bariatric surgery and diet, cancer risk and more…

Filed under:Axial SpondyloarthritisConditionsGout and Crystalline ArthritisMeeting ReportsResearch Rheum Tagged with:2017 ACR/ARHP Annual MeetingACR/ARHP Annual MeetingAnkylosing SpondylitiscardiovascularDASH dietGoutjuvenile idiopathic arthritis (JIA)Knee Osteoarthritis (OA)secukinumab

How Non-Physician Providers Can Help Your Practice

Richard Quinn  |  November 17, 2017

New data shows that both private and public rheumatology practices benefit financially by hiring non-physician providers (NPPs). But when should practices hire NPPs?

Filed under:Practice SupportWorkforce Tagged with:Medical Group Management Associationnon-physician providerPractice Managementrheumatologystaffstaffing

The Rheumatologist Selects Dr. Philip Seo as Physician Editor

Carol Patton  |  November 15, 2017

For the last 20 years, Philip Seo, MD MHS, has trained, worked and conducted research at Johns Hopkins University. As an associate professor of medicine, he also serves in two other roles: as the director of the university’s fellowship training program and director of its vasculitis center. After graduating medical school from Columbia University in…

Filed under:Professional Topics Tagged with:MDMHSPhilip SeoPhysician EditorThe Rheumatologist

What You Need to Know about the New Medicare Card Project

Carina Stanton  |  November 15, 2017

Beginning in April 2018, Medicare patients will receive newly designed Medicare identification cards that replace their Social Security numbers (SSNs) with unique, randomly assigned, alphanumeric identification numbers. The Centers for Medicare & Medicaid Services (CMS) is making the change to protect patients 65 and older from exposing their SSNs in efforts to “help prevent fraud,…

Filed under:Practice SupportProfessional Topics Tagged with:Centers for Medicare & Medicaid Services (CMS)Medicare Access and CHIP Reauthorization Act (MACRA)Medicare cards

Golimumab Receives 2 More FDA Approvals

Michele B. Kaufman, PharmD, BCGP  |  November 15, 2017

The FDA has expanded the indications for golimumab, an anti-TNF-alpha monoclonal antibody, to include the treatment of active psoriatic arthritis and ankylosing spondylitis…

Filed under:Drug Updates

  • « Previous Page
  • 1
  • …
  • 174
  • 175
  • 176
  • 177
  • 178
  • …
  • 330
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences